Navigation Links
Pipeline of Pulmonary Arterial Hypertension Market (PAH) Reviewed for H1 2016 in New Report
Date:4/29/2016

PUNE, India, April 29, 2016 /PRNewswire/ --

ReportsnReports.com adds "Pulmonary Arterial Hypertension - Pipeline Review, H1 2016" market research report that provides an overview of the PAH therapeutic pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

Companies discussed in this Pulmonary Arterial Hypertension Pipeline Review, H1 2016 report include APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celsion Corporation, Complexa, Inc., Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Insmed Incorporated, INVENT Pharmaceuticals, Inc., Johnson & Johnson, Kowa Company, Ltd., Mallinckrodt Plc, Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Morphogen-IX Limited, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis AG, Peloton Therapeutics, Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc., Pulmokine, Inc., Reata Pharmaceuticals, Inc., Respira Therapeutics, Inc., Selten Pharma, Inc, Silence Therapeutics Plc, SteadyMed Therapeutics, Inc., Suda Ltd and Toray Industries, Inc.

Complete report on H1 2016 pipeline review of Pulmonary Arterial Hypertension with 62 market data tables and 16 figures, spread across 202 pages is available at http://www.reportsnreports.com/reports/538046-pulmonary-arterial-hypertension-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Drug profiles discussed in this research report includes Antibody for Pulmonary Arterial Hypertension, Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension, APT-602, bardoxolone methyl, beraprost sodium ER, beraprost sodium SR, BIA-51058, BMP-9, CT-2009, CXA-10, Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension, fasudil, imatinib mesylate, INS-1009, INV-240, JNJ-26993135, lisuride, MFC-001, MFC-002, nitric oxide, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension, PB-1046, PB-1120, pitavastatin NP, PK-10453, PK-10571, PLX-PAD, PT-2977, QCC-374, R-190, ralinepag, RT-234, selexipag, selonsertib, sirolimus albumin-bound, Small Molecule for Pulmonary Arterial Hypertension, Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction, Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension, Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension, Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension, Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension, SPI-054, SPI-183, SUD-004, Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction, Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension, tacrolimus, tadalafil, tiprelestat, tocilizumab, TR-422, treprostinil, treprostinil diolamine, TXA-127, ubenimex and udenafil.

Order a copy of this PAH pipeline report for H1 2016 @ http://www.reportsnreports.com/Purchase.aspx?name=538046 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension and reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Another newly published market research report titled on Portal Hypertension - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Portal Hypertension Pipeline market research report of 73 pages is available at http://www.reportsnreports.com/reports/538071-portal-hypertension-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


'/>"/>
SOURCE ReportsnReports
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Osteoarthritis Pipeline Market H1 2016 Global Review Report
2. Contact Lenses Market Medical Devices Pipeline Assessment 2016 Research Report
3. Frontier Pharma Report: Chronic Obstructive Pulmonary Disease (COPD) Market - Which Molecular Targets Appear Most Frequently in the Pipeline? - Research and Markets
4. Frontier Pharma: Ovarian Cancer Report - What Are The Current Unmet Needs That The Pipeline Needs To Address - Research and Markets
5. Pipeline of Polycythemia Vera Market Reviewed for H1 2016
6. Despite its Weak Pipeline, Schizophrenia Market May Benefit from Drugs Used in Similar Indications, Says GBI Research
7. H1 2016 Lyme Disease Pipeline Market Research Report
8. Substance Abuse Treatment Pipeline Dominated by Nicotine and Alcohol Addiction Treatments, Says GBI Research
9. Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
10. Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
11. Anthrax Market Pipeline Global Review Research Report for H2 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):